PDCD1 and colorectal carcinoma: Together with the finding that ARID3B directly regulates PD-L1, the potential use of anti-PD1 therapy or STAT3 inhibitors to resume antitumor immunity in ARID3B-overexpressing CRC is worthy of further investigation.